Agende from yahoo: "Twenty thousand dermatologists have no interest in a product that the medical regulars have not approved. They prescribe approved medicines to treat diseases affecting the skin. Clinuvel only has one approved drug for treating one disease. Only when Clinuvel gets a second indication approved will practicing dermatologists become interested in that treatment. Clinuvel employs too many people who have nothing of relevance to contribute. In recent years, this has become a burden on the balance sheet. Clinuvel has been trapped in a bank balance of 190 to 200 million for several years. The waste of funds for useless promotion is now the norm. If not for the interest received on the bank balance, there would be no profit to report. Hence a six-year low in the share price. "
He is not very popular among the CUV cheerleaders but his contributions regularly bring it to the point.
CUV Price at posting:
$11.85 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)